Clinical Edge Journal Scan

Breast-conserving surgery without axillary surgery and radiotherapy safe in elderly BC patients


 

Key clinical point: Breast-conserving surgery without axillary lymph node dissection as well as breast and axillary radiotherapy (BCSNR) was safe and resulted in survival rates comparable to mastectomy plus axillary lymph node dissection (MALND) in elderly patients with axillary lymph node-negative breast cancer (BC).

Major finding: At a median follow-up of 5 years, BCSNR vs MALND was not associated with significantly worsened distant recurrence-free survival (98.1% vs 93.2%; P = .990) and BC-specific survival (96.3% vs 99.3%; P = .076) rates but was associated with a significantly higher local recurrence rate (10.3% vs 2.2%; P = .001).

Study details: Findings are from a retrospective study including 541 patients aged ≥70 years with axillary lymph node-negative BC, of which 181 and 360 patients underwent MALND with negative axillary cleaning and BCSNR, respectively.

Disclosures: This study was supported by the CAMS Innovation Fund for Medical Sciences, China, and other sources. The authors declared no conflicts of interest.

Source: Zhong Y et al. Breast-conserving surgery without axillary surgery and radiation versus mastectomy plus axillary dissection in elderly breast cancer patients: A retrospective study. Front Oncol. 2023;13:1126104 (Mar 20). Doi: 10.3389/fonc.2023.1126104

Recommended Reading

Breast conservation safe even with multiple-site tumors
Breast Cancer ICYMI
De-escalation still beneficial after 10 years for some HER2+ breast cancers
Breast Cancer ICYMI
Survival improved for some patients with metastatic cancers
Breast Cancer ICYMI
Outpatient costs top drug costs in some insured, working women with breast cancer
Breast Cancer ICYMI
Weight loss after bariatric surgery may reduce risk of developing breast cancer
Breast Cancer ICYMI
Mastectomy associated with worse frailty in older women with early-stage breast cancer
Breast Cancer ICYMI
Both combined and progestagen-only contraceptives associated with slightly increased BC risk
Breast Cancer ICYMI
Low-dose tamoxifen continues to prevent BC recurrence in breast noninvasive neoplasia
Breast Cancer ICYMI
Worse survival in BRCA1/2 germline mutation carriers receiving ET for HR+/HER2− BC
Breast Cancer ICYMI
Serum thymidine kinase 1 activity: A promising prognostic biomarker in advanced breast cancer
Breast Cancer ICYMI